1. Immune response to the terminal repeat protein of epstein-barr virus in patients with undifferentiated nasopharyngeal carcinoma
- Author
-
Belousova Nv, B. M. Aliev, N. A. Probatova, T. T. Kondrat'eva, Shcherbak Ln, V. E. Gurtsevich, V. S. Alferov, N. A. Mikhailova, Stepina Vn, Pavlish Oa, and Afanas'eva Ta
- Subjects
Indirect immunofluorescence ,biology ,business.industry ,Antibody titer ,General Medicine ,medicine.disease_cause ,medicine.disease ,Epstein–Barr virus ,Virology ,General Biochemistry, Genetics and Molecular Biology ,Virus ,Immune system ,Nasopharyngeal carcinoma ,Immunology ,biology.protein ,Medicine ,In patient ,Antibody ,business - Abstract
Screening of 205 patients suffering from various diseases and healthy donors for the presence of serum antibodies to terminal repeat protein (TP) of Epstein-Barr virus was carried out using the indirect immunofluorescence technique. TP antibodies were detected exclusively in patients with undifferentiated nasopharyngeal carcinoma (in 30–40% of patients within this group). Evaluation of TP antibody titers before and after treatment revealed a correlation between the dynamics of these antibodies and the clinical prognosis of patients.
- Published
- 1995
- Full Text
- View/download PDF